nanotech investing Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
nanotech investing Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
nanotech investing Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
nanotech investing Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
nanotech investing PRAME-directed Cell Therapy Using Immatics' TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
nanotech investing Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
nanotech investing Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
